14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.
Takeda California
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.
Sichuan University
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.
University of Calabria
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
Revolution Medicines
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).
University of Hradec Kralove
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.
University of Basel
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
University of Basel
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.
Cellzome
Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.
Nestl�
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
University of Basel
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.
China Pharmaceutical University